{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:55:13Z","timestamp":1791312913927,"version":"4.3.1"},"reference-count":87,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["heartfailure.theclinics.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.hfc.2015.08.021","type":"journal-article","created":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T02:00:22Z","timestamp":1457488822000},"page":"257-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation"],"prefix":"10.1016","volume":"12","author":[{"given":"Mikhail S.","family":"Dzeshka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.hfc.2015.08.021_bib1","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.hfc.2015.08.021_bib2","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1161\/STROKEAHA.113.002329","article-title":"Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study","volume":"44","author":"Bj\u00f6rck","year":"2013","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.hfc.2015.08.021_bib3","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/01.STR.32.2.392","article-title":"Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project)","volume":"32","author":"Lamassa","year":"2001","journal-title":"Stroke"},{"issue":"17","key":"10.1016\/j.hfc.2015.08.021_bib4","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1212\/WNL.0b013e31828f1828","article-title":"Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke","volume":"80","author":"Cotter","year":"2013","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.hfc.2015.08.021_bib5","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.hfc.2015.08.021_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2015.08.021_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2013.12.022","article-title":"\u2018Real-world\u2019 antithrombotic treatment in atrial fibrillation: the EURObservational Research Programme Atrial Fibrillation General Pilot survey","author":"Lip","year":"2014","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.hfc.2015.08.021_bib8","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","article-title":"Independent predictors of stroke in patients with atrial fibrillation: a systematic review","volume":"69","author":"Stroke Risk in Atrial Fibrillation Working Group","year":"2007","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.hfc.2015.08.021_bib9","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1253\/circj.CJ-12-1036","article-title":"Stroke and thromboembolism in atrial fibrillation","volume":"76","author":"Pisters","year":"2012","journal-title":"Circ J"},{"issue":"2","key":"10.1016\/j.hfc.2015.08.021_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.hfc.2015.08.021_bib11","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"issue":"22","key":"10.1016\/j.hfc.2015.08.021_bib12","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.hfc.2015.08.021_bib13","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1160\/TH12-03-0175","article-title":"The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0\u20131: a nationwide cohort study","volume":"107","author":"Olesen","year":"2012","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.hfc.2015.08.021_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1538-7836.2010.04085.x","article-title":"A\u00a0comparison of risk stratification schema for stroke in 79884 atrial fibrillation patients in general practice","volume":"9","author":"Van Staa","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"10.1016\/j.hfc.2015.08.021_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/CIRCEP.111.966713","article-title":"Reliable identification of \u2018truly low\u2019 thromboembolic risk in patients initially diagnosed with \u2018lone\u2019 atrial fibrillation: the Belgrade Atrial Fibrillation Study","volume":"5","author":"Potpara","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"5","key":"10.1016\/j.hfc.2015.08.021_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-151-5-200909010-00003","article-title":"The net clinical benefit of warfarin anticoagulation in atrial fibrillation","volume":"151","author":"Singer","year":"2009","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.hfc.2015.08.021_bib17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH11-05-0364","article-title":"Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a \u2018real world\u2019 nationwide cohort study","volume":"106","author":"Olesen","year":"2011","journal-title":"Thromb Haemost"},{"issue":"19","key":"10.1016\/j.hfc.2015.08.021_bib18","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish Atrial Fibrillation Cohort Study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hfc.2015.08.021_bib19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","article-title":"Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a \u2018real world\u2019 atrial fibrillation population: a modeling analysis based on a nationwide cohort study","volume":"107","author":"Banerjee","year":"2012","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.hfc.2015.08.021_bib20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A\u00a0novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.hfc.2015.08.021_bib21","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2012.06.019","volume":"60","author":"Apostolakis","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.hfc.2015.08.021_bib22","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1586\/14779072.2013.839214","article-title":"Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial fibrillation","volume":"11","author":"Overvad","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"10.1016\/j.hfc.2015.08.021_bib23","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.ijcard.2012.12.076","article-title":"Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chi-Shan Community Cohort Study","volume":"168","author":"Lip","year":"2013","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.hfc.2015.08.021_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1160\/TH11-12-0827","article-title":"The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the National Multicentre BNK Online Bridging Registry (BORDER)","volume":"108","author":"Omran","year":"2012","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.hfc.2015.08.021_bib25","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.hfc.2015.08.021_bib26","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1160\/TH13-06-0443","article-title":"Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis\u2013Task Force on Anticoagulants in Heart Disease","volume":"110","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.hfc.2015.08.021_bib27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","article-title":"European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"15","author":"Heidbuchel","year":"2013","journal-title":"Europace"},{"issue":"7 Suppl","key":"10.1016\/j.hfc.2015.08.021_bib28","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.cjca.2013.04.002","article-title":"Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban","volume":"29","author":"Gong","year":"2013","journal-title":"Can J Cardiol"},{"issue":"12","key":"10.1016\/j.hfc.2015.08.021_bib29","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2165\/11595540-000000000-00000","article-title":"Edoxaban: a new oral direct factor Xa inhibitor","volume":"71","author":"Camm","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.hfc.2015.08.021_bib30","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.hfc.2015.08.021_bib31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2015.08.021_bib32","article-title":"Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China National Stroke Registry","author":"Wang","year":"2013","journal-title":"J\u00a0Stroke Cerebrovasc Dis"},{"issue":"2","key":"10.1016\/j.hfc.2015.08.021_bib33","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1160\/TH11-06-0388","article-title":"Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy","volume":"107","author":"Horne","year":"2012","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.hfc.2015.08.021_bib34","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1160\/TH12-03-0151","article-title":"Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction","volume":"108","author":"Kurnik","year":"2012","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.hfc.2015.08.021_bib35","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1160\/TH12-05-0362","article-title":"Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation","volume":"108","author":"Xu","year":"2012","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.hfc.2015.08.021_bib36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.thromres.2008.09.016","article-title":"Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control","volume":"124","author":"Morgan","year":"2009","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.hfc.2015.08.021_bib37","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH11-05-0353","article-title":"Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients","volume":"106","author":"Gallagher","year":"2011","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.hfc.2015.08.021_bib38","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1378\/chest.129.5.1155","article-title":"Effect of study setting on anticoagulation control: a systematic review and metaregression","volume":"129","author":"van Walraven","year":"2006","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.hfc.2015.08.021_bib39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1160\/TH09-05-0327","article-title":"New oral anticoagulant drugs in cardiovascular disease","volume":"104","author":"Ahrens","year":"2010","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.hfc.2015.08.021_bib40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.beha.2013.07.008","article-title":"Novel oral anticoagulants in non-valvular atrial fibrillation","volume":"26","author":"Potpara","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"10.1016\/j.hfc.2015.08.021_bib41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1160\/TH12-10-0772","article-title":"General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease","volume":"109","author":"De Caterina","year":"2013","journal-title":"Thromb Haemost"},{"issue":"Suppl 2","key":"10.1016\/j.hfc.2015.08.021_bib42","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0049-3848(10)70147-X","article-title":"Factor Xa and thrombin as targets for new oral anticoagulants","volume":"127","author":"Weitz","year":"2011","journal-title":"Thromb Res"},{"issue":"12","key":"10.1016\/j.hfc.2015.08.021_bib43","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hfc.2015.08.021_bib44","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hfc.2015.08.021_bib45","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.hfc.2015.08.021_bib46","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.hfc.2015.08.021_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001768","article-title":"Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database","volume":"2","author":"Lee","year":"2012","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.hfc.2015.08.021_bib48","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial","volume":"9","author":"Diener","year":"2010","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.hfc.2015.08.021_bib49","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1474-4422(12)70042-X","article-title":"Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF","volume":"11","author":"Hankey","year":"2012","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.hfc.2015.08.021_bib50","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial","volume":"11","author":"Easton","year":"2012","journal-title":"Lancet Neurol"},{"issue":"19","key":"10.1016\/j.hfc.2015.08.021_bib51","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMc1007378","article-title":"Newly identified events in the RE-LY trial","volume":"363","author":"Connolly","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hfc.2015.08.021_bib52","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.112.001139","article-title":"The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) Study","volume":"128","author":"Connolly","year":"2013","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.hfc.2015.08.021_bib53","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in \u201creal-world\u201d patients with atrial fibrillation: a prospective nationwide cohort study","volume":"61","author":"Larsen","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.hfc.2015.08.021_bib54","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/CIRCULATIONAHA.112.115410","article-title":"Efficacy and safety of the novel oral anticoagulants in atrial fibrillation","volume":"126","author":"Dentali","year":"2012","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.hfc.2015.08.021_bib55","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7326\/0003-4819-157-10-201211200-00532","article-title":"Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism","volume":"157","author":"Adam","year":"2012","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.hfc.2015.08.021_bib56","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jacc.2012.03.019","article-title":"Indirect comparisons of new oral anticoagulants for efficacy and safety when used for stroke prevention in atrial fibrillation","volume":"60","author":"Lip","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.hfc.2015.08.021_bib57","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1160\/TH12-02-0093","article-title":"An indirect comparison of dabigatran, rivaroxaban, and apixaban for atrial fibrillation","volume":"108","author":"Mantha","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hfc.2015.08.021_bib58","doi-asserted-by":"crossref","first-page":"e7097","DOI":"10.1136\/bmj.e7097","article-title":"Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis","volume":"345","author":"Rasmussen","year":"2012","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.hfc.2015.08.021_bib59","doi-asserted-by":"crossref","DOI":"10.1160\/TH14-02-0118","article-title":"Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis","volume":"111","author":"Skj\u00f8th","year":"2014","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.hfc.2015.08.021_bib60","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1160\/TH11-11-0804","article-title":"Impact of dabigatran on a large panel of routine or specific coagulation assays","volume":"107","author":"Douxfils","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hfc.2015.08.021_bib61","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/15748901112079990013","article-title":"Current status and ongoing development of reversing agents for novel oral anticoagulants","volume":"8","author":"Capodannoa","year":"2013","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"issue":"5","key":"10.1016\/j.hfc.2015.08.021_bib62","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.hfc.2015.08.021_bib63","doi-asserted-by":"crossref","DOI":"10.1378\/chest.13-2976","article-title":"Relationship of the SAMe-TT2R2 score to poor quality anticoagulation, stroke, clinically relevant bleeding and mortality in patients with atrial fibrillation","author":"Lip","year":"2014","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.hfc.2015.08.021_bib64","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/europace\/eul097","volume":"8","author":"Fuster","year":"2006","journal-title":"Europace"},{"issue":"8","key":"10.1016\/j.hfc.2015.08.021_bib65","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jacc.2007.09.065","article-title":"Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation","volume":"51","author":"Fang","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2015.08.021_bib66","article-title":"Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks","author":"Aguilar","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.hfc.2015.08.021_bib67","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/01.STR.0000198839.61112.ee","article-title":"Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial","volume":"37","author":"Sato","year":"2006","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.hfc.2015.08.021_bib68","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hfc.2015.08.021_bib69","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1474-4422(12)70017-0","article-title":"Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial","volume":"11","author":"Diener HC","year":"2012","journal-title":"Lancet Neurol"},{"issue":"20","key":"10.1016\/j.hfc.2015.08.021_bib70","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"ACTIVE Investigators","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"9526","key":"10.1016\/j.hfc.2015.08.021_bib71","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"ACTIVE Writing Group of the ACTIVE Investigators","year":"2006","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.hfc.2015.08.021_bib72","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1160\/TH10-05-0332","article-title":"Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes","volume":"104","author":"Depta","year":"2010","journal-title":"Thromb Haemost"},{"issue":"9658","key":"10.1016\/j.hfc.2015.08.021_bib73","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","article-title":"Mechanisms of thrombogenesis in atrial fibrillation: Virchow\u2019s triad revisited","volume":"373","author":"Watson","year":"2009","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.hfc.2015.08.021_bib74","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/j.1538-7836.2004.00899.x","article-title":"Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi","volume":"2","author":"Wysokinski","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.hfc.2015.08.021_bib75","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation","volume":"26","author":"Nieuwlaat","year":"2005","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hfc.2015.08.021_bib76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH09-08-0580","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary intervention\/stenting","volume":"103","author":"Lip","year":"2010","journal-title":"Thromb Haemost"},{"issue":"10","key":"10.1016\/j.hfc.2015.08.021_bib77","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.hfc.2015.08.021_bib78","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1378\/chest.08-0350","article-title":"Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting","volume":"134","author":"Manzano-Fernandez","year":"2008","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.hfc.2015.08.021_bib79","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1160\/TH12-08-0542","article-title":"The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation","volume":"109","author":"Azoulay","year":"2013","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.hfc.2015.08.021_bib80","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1160\/TH13-04-0351","article-title":"Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation","volume":"110","author":"Bernard","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.hfc.2015.08.021_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/clc.22254","article-title":"One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry","author":"Rubboli","year":"2014","journal-title":"Clin Cardiol"},{"issue":"11","key":"10.1016\/j.hfc.2015.08.021_bib82","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9872","key":"10.1016\/j.hfc.2015.08.021_bib83","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2015.08.021_bib84","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.113.004834","article-title":"Antiplatelet therapy in stable coronary artery disease in atrial fibrillation patients on oral anticoagulant: a nationwide cohort study","author":"Lamberts","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.hfc.2015.08.021_bib85","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.athoracsur.2006.11.094","article-title":"Guidelines for reporting data and outcomes for the surgical treatment of atrial fibrillation","volume":"83","author":"Shemin","year":"2007","journal-title":"Ann Thorac Surg"},{"issue":"9689","key":"10.1016\/j.hfc.2015.08.021_bib86","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.hfc.2015.08.021_bib87","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/CIRCULATIONAHA.108.844779","article-title":"Left atrial appendage occlusion does not eliminate the need for warfarin","volume":"120","author":"Whitlock","year":"2009","journal-title":"Circulation"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713615000896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713615000896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T13:27:38Z","timestamp":1536931658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713615000896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1551713615000896"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2015.08.021","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2015.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}